New Zealand Permits Two Psychiatrists to Use MDMA for PTSD Therapy
New Zealand’s medicines and medical devices safety authority (Medsafe) has officially granted limited approval to two licensed psychiatrists to prescribe pharmaceutical-quality 3,4-methylenedioxymethamphetamine (MDMA). The psychoactive substance is to be used as part of a specialised psychotherapy programme for adult patients suffering from post-traumatic stress disorder (PTSD).
PTSD is a severe mental health condition triggered after a person experiences or witnesses a traumatic event, such as war, natural disasters, tragic accidents or sexual violence.
MDMA is a psychoactive substance better known to the public as ecstasy, E, XTC or molly. The substance has stimulant effects and can alter a person’s perception and emotional experience.
In its medical use in New Zealand, the MDMA administered is a pharmaceutical-grade product, not the illegal product circulated as ecstasy. Its use is carried out under strict clinical supervision.
The therapeutic use of MDMA is intended as an additional option for adults with PTSD whose symptoms have not responded to conventional therapy.
The approach is known as MDMA-assisted psychotherapy. The treatment combines psychotherapy with the use of pharmaceutical-grade MDMA within a broader care programme.
However, evidence regarding the use of MDMA for PTSD continues to evolve. The New Zealand government says further research is still needed, particularly to assess safety and determine appropriate therapy protocols.
The approval for MDMA use in New Zealand comes with a number of restrictions.
To obtain approval, psychiatrists must also demonstrate sufficient expertise and provide detailed information on how the therapy will be carried out safely and appropriately. Medsafe weighed the benefit of making a new treatment option available against the need to protect patients from potential risks.
The approval does not mean MDMA has been approved as a medicine for general use in New Zealand. Its use for PTSD remains limited to the two psychiatrists who have received Medsafe’s approval, while other clinicians wishing to prescribe it must apply for separate approval.
The use of MDMA in New Zealand is currently permitted only on a limited and controlled basis for certain patients, and not for unrestricted use.
Source: jawawa.id (https://jawawa.id/newsitem/new-zealand-permits-two-psychiatrists-to-use-mdma-for-ptsd-therapy-1788846677)
Originally published by Media Indonesia (https://mediaindonesia.com/kesehatan/930922/selandia-baru-izinkan-dua-psikiater-gunakan-mdma-untuk-terapi-ptsd), translated from Indonesian